A Pilot Study to Explore Serum and Imaging Biomarkers in Patients With Spinal Cord Compression
2 other identifiers
observational
30
1 country
1
Brief Summary
One of the complications of having cancer in the spinal vertebrae is that it can spread and lead to compression of the spinal cord. Spinal cord compression is a serious event that needs to be treated quickly in order to prevent permanent damage to the spinal cord and nerves.
- Researchers currently do not have the ability to accurately predict whether cancer of the vertebrae will cause spinal cord compression. It is possible that accurate predictions could allow doctors to treat patients even before they develop symptoms of spinal cord compression, thereby preventing some of the long-term consequences. Objectives:
- To compare patients with cancer of the spinal vertebrae with and without symptoms of spinal cord compression by looking at markers in the blood and changes on novel magnetic resonance imaging (MRI) techniques that might allow researchers to predict who will experience spinal cord compression before they actually begin to have symptoms. Eligibility:
- One group of healthy volunteers 18 years of age and older.
- One group of patients 18 years of age and older who have cancer that has spread to the vertebrae without symptoms of spinal cord compression.
- One group of patients 18 years of age and older who have cancer that has spread to the vertebrae with symptoms of spinal cord compression. Design:
- Healthy volunteers:
- Blood will be drawn from each volunteer for initial tests and for more specific biomarker tests.
- Comprehensive MRI of the spine, followed by a special type of MRI called diffusion tensor imaging (DTI). It is believed that DTI may be even more sensitive in revealing spinal cord abnormalities than regular MRI sequences.
- Patients with cancer of the vertebrae:
- Researchers will obtain information such as pathology reports, laboratory results, diagnosis and treatment history, physical exam (PE) information, results of scans such as x-rays, MRI, computerized tomography (CT), and positron emission tomography (PET), and planned treatment details.
- Additional blood samples will be taken for specific biomarker tests.
- Questionnaire about pain, unusual sensations or numbness, bladder or bowel problems, and mobility.
- Comprehensive MRI of the spine, followed by a DTI.
- Patients who appear to have symptoms of spinal cord compression will be offered standard radiation treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Mar 2009
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 31, 2009
CompletedFirst Submitted
Initial submission to the registry
June 24, 2009
CompletedFirst Posted
Study publicly available on registry
June 25, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
April 10, 2012
CompletedJuly 2, 2017
April 10, 2012
June 24, 2009
June 30, 2017
Conditions
Keywords
Eligibility Criteria
You may qualify if:
- Age greater than or equal to 18 years
You may not qualify if:
- Inability to provide informed consent.
- History or concomitant central nervous system injury or inflammatory disease (such as stroke, trauma or multiple sclerosis).
- History of radiation therapy to CNS.
- History of brain or spinal cord surgical procedure.
- Contraindication for MR scanning:
- cardiac pacemaker
- metallic foreign body (metal sliver) in their eye, or who have an aneurysm clip in their skull
- severe claustrophobia
- metallic orthopedic or other implants
- Allergy to MRI contrast agent.
- Compromised renal function (serum creatinine greater than 1.5) unless patient is on dialysis.
- ELIGIBILITY CRITERIA FOR PATIENT PARTICIPANTS
- Age greater than or equal to 18 years
- Histologically confirmed cancer.
- Metastatic lesions in the spinal vertebrae, confirmed by CT/MRI/Bone Scan.
- +18 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
Related Publications (3)
Gabriel K, Schiff D. Metastatic spinal cord compression by solid tumors. Semin Neurol. 2004 Dec;24(4):375-83. doi: 10.1055/s-2004-861532.
PMID: 15637649BACKGROUNDBrihaye J, Ectors P, Lemort M, Van Houtte P. The management of spinal epidural metastases. Adv Tech Stand Neurosurg. 1988;16:121-76. doi: 10.1007/978-3-7091-6954-4_4. No abstract available.
PMID: 3064753BACKGROUNDMarquardt G, Setzer M, Seifert V. Protein S-100b as serum marker for prediction of functional outcome in metastatic spinal cord compression. Acta Neurochir (Wien). 2004 May;146(5):449-52. doi: 10.1007/s00701-004-0242-3. Epub 2004 Mar 22.
PMID: 15118880BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Susan E Bates, M.D.
National Cancer Institute (NCI)
Study Design
- Study Type
- observational
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- NIH
Study Record Dates
First Submitted
June 24, 2009
First Posted
June 25, 2009
Study Start
March 31, 2009
Study Completion
April 10, 2012
Last Updated
July 2, 2017
Record last verified: 2012-04-10